Shahrin Ahmed: New treatment for a form of acute myeloid leukaemia approved for use on NHS – UK

Shahrin Ahmed, Medical Specialist at Canadian Cancer Society, made the following post on X:

“Blood cancer treatment for a form of acute myeloid leukaemia approved for use on NHS – UK

Newly diagnosed patients with AML with an IDH1 mutation now have access to a new treatment – Ivosidenib (Tibsovo) with azacitidine. It is now accessible to those in England and Wales through the National Institute for Health and Care Excellence (NICE). Earlier this year, the treatment combination was already approved for use in Scotland.

Acute myeloid leukaemia is a blood cancer that rapidly progresses and usually necessitates immediate treatment. Intense chemotherapy may not be suitable for AML patients with an IDH1 mutation due to their age and pre-existing medical conditions. In the UK, approximately 3,100 people are diagnosed with AML every year.

This is the initial treatment designed specifically for individuals with acute myeloid leukemia who have an IDH1 mutation and are unable to receive standard induction chemotherapy.”

Source: Shahrin Ahmed/X